Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Diurnal Group plc
  6. News
  7. Summary
    DNL   GB00BDB6Q760


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Diurnal : US FDA Accepts NDA Application for Alkindi

02/13/2020 | 02:07am EST
Regulatory Story
Go to market news section
US FDA Accepts NDA Application for Alkindi
Released 07:00 13-Feb-2020

RNS Number : 8355C
Diurnal Group PLC
13 February 2020

13 February 2020

Diurnal Group plc

('Diurnal' or the 'Company')

US FDA Accepts for Review Diurnal's New Drug Application for Alkindi® Sprinkle

Application seeks approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents

NDA could potentially be approved in Q3 2020

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that its New Drug Application (NDA) for Alkindi®(hydrocortisone granules in capsules for opening), to be known in the US as Alkindi®Sprinkle, has been accepted for review by the US Food and Drug Administration (FDA). Diurnal is seeking approval of Alkindi®Sprinkle as a replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents (from birth to

Paediatric AI is a condition characterised by deficiency in cortisol, an essential hormone in regulating growth, metabolism and the response to stress. Paediatric AI has been identified as an orphan disease in the US where there are estimated to over 4,000 sufferers under the age of 17. Untreated, the disease is associated with significant morbidity and increased mortality.

The NDA for Alkindi® Sprinkle was submitted in November 2019 following a positive meeting with the FDA in Q1 2019 which confirmed Diurnal's clinical and regulatory pathway for the product in the US. The PDUFA date set by the FDA, which would be the earliest date at which approval could occur, is 29 September 2020.

Martin Whitaker, CEO of Diurnal, commented:

'We are pleased to announce that our NDA for Alkindi®Sprinkle in the US has been accepted for review by the FDA. If approved, Alkindi® Sprinkle will provide a major breakthrough in the US as the only licensed treatment specifically designed for use in children with adrenal insufficiency, where there is a significant unmet patient need.'

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For further information, please visit www.diurnal.co.ukor contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: James Stearns

Cantor Fitzgerald Europe (Joint Broker)

+44 (0)20 7894 7000

Corporate Finance: Phil Davies, Will Goode, Michael Boot

Healthcare Equity Sales: Andrew Keith

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Notes to Editors

About Alkindi®Sprinkle (hydrocortisone granules in capsules for opening)

Alkindi®Sprinkle is a patented, oral, immediate-release paediatric formulation of hydrocortisone granules in capsules for opening. Alkindi®Sprinkle comes in dose strengths consistent with age-appropriate dosing in children. This therapeutic approach has the potential to help young patients less than seventeen years of age suffering from diseases due to cortisol deficiency including paediatric AI and congenital adrenal hyperplasia (CAH) in the US. The European Commission has granted a paediatric use marketing authorisation (PUMA) for Alkindi®as replacement therapy of AI in infants, children and adolescents (from birth to

About Paediatric Adrenal Insufficiency

Paediatric AI, including the genetic condition CAH is a condition characterised by deficiency in cortisol, an essential hormone in regulating metabolism and the response to stress. The primary symptoms of AI are chronic fatigue and patients are at risk of adrenal crisis and death if they do not have adequate cortisol replacement. AI is either primary or secondary, with primary AI resulting from diseases intrinsic to the adrenal gland and secondary AI resulting from pituitary diseases where there is a failure of stimulation of the adrenal by the pituitary of the signalling hormone ACTH (adrenocorticotropic hormone).

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

Date of Preparation: February 2020 Code: Inf US-USA-0005

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
©2014London Stock Exchange plc. All rights reserved

US FDA Accepts NDA Application for Alkindi - RNS


Diurnal Group plc published this content on 13 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 February 2020 07:05:17 UTC

ę Publicnow 2020
All news about DIURNAL GROUP PLC
11/16FTSE 100 Slips Over Rising Wages, Gas-Price Concerns
11/16Diurnal Group Gets Marketing Authorization For Adrenal Insufficiency Drug In Switzerlan..
11/16FTSE 100 Down Despite Gains for Diageo, Vodafone
11/16DIURNAL : Alkindi« approved by Swissmedic for use in Switzerland
11/16Diurnal Group plc Announces Alkindi Approves for Use in Switzerland
11/15DIURNAL : Eton Pharmaceuticals enters into US co-promotion deal for Alkindi Sprinkle«
11/15FTSE 100 Closes Down as Pound Strengthens Over Euro
11/15INSIDER SELL : Skyworks Solutions
11/15FTSE Edges Lower, Rates Traders to Focus on Data Amid Muted Gilt Supply
11/15FTSE 100 Flat, Pound Seen Rising on Data as Traders Brush Aside Brexit
More news
Sales 2022 8,84 M 11,7 M 11,7 M
Net income 2022 -13,0 M -17,3 M -17,3 M
Net cash 2022 19,1 M 25,3 M 25,3 M
P/E ratio 2022 -6,80x
Yield 2022 -
Capitalization 96,4 M 127 M 128 M
EV / Sales 2022 8,74x
EV / Sales 2023 3,81x
Nbr of Employees 33
Free-Float 96,0%
Duration : Period :
Diurnal Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIURNAL GROUP PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 57,00 GBX
Average target price 166,00 GBX
Spread / Average Target 191%
EPS Revisions
Managers and Directors
Martin James Whitaker Chief Executive Officer & Executive Director
Richard Edward Bungay CFO, Secretary & Executive Director
Karl Anders Olof Hńrfstrand Non-Executive Chairman
Richard John Martin Ross Executive Director & Chief Scientific Officer
John Porter Medical Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010